

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

CIRC BREAKS THROUGH IN KEY RAW MATERIAL TECHNOLOGY FOR BREATH DIAGNOSIS AND EMERGES AS A LEADING ENTERPRISE WITH COMPLETE CONTROL OF THE ENTIRE INDUSTRIAL CHAIN FOR BREATH TEST PRODUCTS

This announcement is voluntarily made by China Isotope & Radiation Corporation (“**CIRC**” or the “**Company**”) to keep its shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 31 October, CIRC has launched the carbon isotope product, marking China’s breakthrough in tackling the bottleneck problems of high-end technology in the field of stable isotopes. This development positioned China among the world’s few nations possessing the capability to produce high-abundance ^{13}CO gas and carbon-13 urea active pharmaceutical ingredients (APIs).

High-abundance ^{13}CO gas serves as the critical raw material for detecting *Helicobacter pylori* infection in urea breath tests. This formal product launch indicated that CIRC has put an end to the nation’s complete reliance on imported ^{13}CO for urea breath test materials. This achievement substantially enhances China’s R&D and production capabilities for stable isotope products, signifying China’s progressive advancement to the forefront of global research and application in stable isotope technology. CIRC has emerged as the leading enterprise with complete control of the entire industrial chain for breath test products.

On the same day, CIRC officially commenced the phase II construction of its stable isotope base project. Upon completion of the project, CIRC will establish a stable supply capacity for high-abundance ^{13}CO gas, carbon-13 urea APIs, and other APIs covering gastrointestinal disease treatments. This development holds profound significance for enhancing public health standards, promoting high-quality development in medical isotopes, and supporting the Healthy China Initiative.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 31 October 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.